AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2653552
Drug: Short overall
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short overall treatment times (less than or equal to 4 weeks)
Trial: 2653552
Drug: Long overall
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long overall treatment times (greater than 4 weeks)
Trial: 355965
Drug: Preoperative ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative ibuprofen
Trial: 29117309
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (daily capsule with 109 total colony-forming units of Bifidobacterium lactis CECT 8145, B longum CECT 7347, Lactobacillus casei CECT 9104)
Trial: 29117309
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (maltodextrin-only capsules)
Trial: 20737519
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Panax ginseng (G115)
Trial: 20737519
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Panax ginseng (G115)
Trial: 18788838
Drug: Zolmitriptan 2.5
RxNorm normalized name: zolmitriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 2.5 mg three times daily
Trial: 18788838
Drug: Zolmitriptan 2.5
RxNorm normalized name: zolmitriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 2.5 mg twice daily
Trial: 15882219
Drug: Sub-antimicrobial dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-antimicrobial dose doxycycline (SDD) 20 mg twice daily with scaling and root planing (SRP)
Trial: 12851185
Drug: Weekly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly group exercise programme with ancillary home exercises
Trial: 11026650
Drug: TNF‐α infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α infusion without pretreatment
Trial: 11026650
Drug: TNF‐α infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α infusion after acetylsalicylic acid pretreatment
Trial: 11026650
Drug: TNF‐α infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α infusion after N(G)‐monomethyl‐L‐arginine pretreatment
Trial: 1880092
Drug: Amoxycillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (500 mg tds)
Trial: 1880092
Drug: Amoxycillin/Clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/Clavulanic acid (Augmentin; 750 mg tds)
Trial: 1880092
Drug: Intravenous Augmentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Augmentin (1.2 g 8 hourly for 3 days, followed by oral doses as above for 7 days)
Trial: 31070146
Drug: Intravenous Augmentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Augmentin
Trial: 7146263
Drug: Bromazepam, 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam, 18 mg/day
Trial: 29101597
Drug: 4.3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.3 g/day n-3 PUFA supplements
Trial: 29101597
Drug: 4.3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.3 g/day n-3 PUFA supplements vs Placebo
Trial: 26756752
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and parenteral prophylaxis (1 g cefmetazole before and every 3 h during surgery plus 1 g oral kanamycin and 750 mg metronidazole twice on the day before surgery)
Trial: 26756752
Drug: Parenteral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral prophylaxis alone (1 g cefmetazole before and every 3 h during surgery)
Trial: 26756752
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and parenteral prophylaxis
Trial: 26756752
Drug: Parenteral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral prophylaxis alone
Trial: 24670025
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline (5 mL)
Trial: 24670025
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (5 mL)
Trial: 18981485
Drug: MK‐677, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐677, 25 mg, once daily
Trial: 15979192
Drug: Sertraline, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline, 50 mg/24 h
Trial: 15979192
Drug: Ultrasonography and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography and physical therapy (15 sessions of 1 W/cm2 on cervical trigger points)
Trial: 12439086
Drug: G(1): 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(1): 8 x 60% T(max) at P(max), 1:2 work:recovery ratio
Trial: 12439086
Drug: G(2): 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(2): 8 x 60% T(max) at P(max), recovery at 65% HR(max)
Trial: 12439086
Drug: G(3): 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(3): 12 x 30 s at 175% PPO, 4.5-min recovery
Trial: 12439086
Drug: G(CON): Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(CON): Control group
Trial: 12161053
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day losartan
Trial: 12161053
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day fosinopril
Trial: 9802743
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg vitamin E for 6 months
Trial: 8567766
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa) 0.1 mg s.c.
Trial: 668773
Drug: Hydrochlorothiazide 75
RxNorm normalized name: triamterene/hydrochlorothiazide 75 mg-50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 75 mg
Trial: 668773
Drug: Hydrochlorothiazide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (various doses)
Trial: 28389484
Drug: Personal frequency-modulated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personal frequency-modulated systems (FMs) used daily over 10 weeks by 4 patients (intervention care subjects)
Trial: 25842726
Drug: Short heating
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short heating time length group (15 min of moxibustion therapy)
Trial: 25842726
Drug: Moderate heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate heating time length group (30 min of moxibustion therapy)
Trial: 25842726
Drug: Long heating
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long heating time length group (60 min of moxibustion therapy)
Trial: 15006188
Drug: APV/RTV 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APV/RTV 600/100 mg twice daily
Trial: 11709566
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (same regimen administered postoperatively)
Trial: 9304332
Drug: Intranasal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunization with inactivated influenza vaccine (IIV)
Trial: 8105790
Drug: Nalmefene augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene augmentation
Trial: 3301925
Drug: Intralesional fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional fluorouracil (1 ml of 50 mg/ml)
Trial: 3301925
Drug: Control lesions
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lesions (no treatment)
Trial: 30870576
Drug: Zoledronate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (4 mg doses, two annual doses)
Trial: 21510461
Drug: Acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50 mg) + Metformin (500 mg) bid/tid (n=115)
Trial: 21510461
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg) bid/tid (n=114)
Trial: 12616661
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch 5% (Lidoderm)
Trial: 12616661
Drug: Extended application
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended application of lidocaine patch 5%
Trial: 12616661
Drug: Continuous application
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous application of up to four patches per day
Trial: 10623695
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg administered intravenously every month
Trial: 6386481
Drug: miniheparin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miniheparin (2 X 2500 IU daily)‐dihydroergotamine
Trial: 6386481
Drug: conventional low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional low‐dose heparin
Trial: 26354539
Drug: Beef ingestion
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef ingestion (30 g protein)
Trial: 26354539
Drug: Milk ingestion
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk ingestion (30 g protein)
Trial: 23301686
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR 10 mg + Naloxone PR 5 mg
Trial: 23301686
Drug: Oxycodone PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone PR 10 mg
Trial: 17926079
Drug: ALA and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA and Photofrin fluorescence-guided resection and repetitive photodynamic therapy (PDT)
Trial: 17132752
Drug: Lanreotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide treatment
Trial: 9819045
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of factor VIII (FVIII) concentrates
Trial: 9819045
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of factor IX (FIX) concentrates
Trial: 9819045
Drug: Control non-haemophilic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control non-haemophilic patients with heparin prophylaxis
Trial: 9819045
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of 50 U/kg of a very high purity clotting factor concentrate
Trial: 7659762
Drug: Amphetamine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (oral administration before learning)
Trial: 7659762
Drug: Amphetamine (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (intramuscular injection after learning)
Trial: 2757893
Drug: 155 mg
RxNorm normalized name: lanolin 155 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 155 mg oral tablet of hydroxychloroquine
Trial: 2757893
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 155 mg racemic hydroxychloroquine
Trial: 334473
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg flurbiprofen 3-times daily for 3 weeks
Trial: 30647912
Drug: DSF combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSF combined with nutritional copper supplement (DSF-Cu) as an adjuvant to alkylating chemotherapy
Trial: 22173608
Drug: PVP combined
RxNorm normalized name: PVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP combined with chemotherapy
Trial: 15730579
Drug: Anterior subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior subcutaneous transposition
Trial: 7420563
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment with penicillin-G
Trial: 7420563
Drug: 10-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day treatment with trimethoprim-sulfamethoxazole
Trial: 27377450
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy for Recovery of Self-Esteem (CBGTRS), 12 group sessions
Trial: 22267373
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 100 mg daily for 5 days
Trial: 12685522
Drug: Ritalin LA,
RxNorm normalized name: Ritalin LA, (50/50 release) 10 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin LA, Metadate CD, Concerta, Adderall XR (new long-acting formulations of MPH and AMP)
Trial: 12685522
Drug: Bolus delivery
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus delivery (BD) and controlled delivery (CD) processes used in drug delivery systems
Trial: 1866002
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg dipyridamole and 330 mg acetylsalicylic acid tid
Trial: 7102534
Drug: Pindolol, 10
RxNorm normalized name: Pindolol, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol, 10 mg twice a day (n = 7)
Trial: 7102534
Drug: Propranolol, median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, median dose 80 mg three times a day (n = 9)
Trial: 7102534
Drug: Metoprolol, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 150 mg twice a day (n = 8)
Trial: 27987040
Drug: Atorvastatin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 60 mg (AT60, n=16)
Trial: 27987040
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg (AT20, n=14)
Trial: 27987040
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with atorvastatin (both doses)
Trial: 27009449
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (0.625 mg/0.025 ml)
Trial: 27009449
Drug: Conventional indirect
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional indirect laser therapy
Trial: 24487616
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment as usual, no exercise)
Trial: 17321110
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (10 mg, three times weekly for 6 months)
Trial: 1505561
Drug: Trimetazidine 6
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 6 mg
Trial: 27387325
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m² for six cycles
Trial: 24664649
Drug: Nurse-initiated treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-initiated treatment
Trial: 24664649
Drug: Physician-initiated treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-initiated treatment
Trial: 20071644
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (2 g purified EPA/DHA)
Trial: 15902529
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Gram stain, culture, and detection of pneumococcal antigen
Trial: 12154113
Drug: Acute ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute ascorbic acid infusion
Trial: 9926739
Drug: Ticarcillin/clavulanate 3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin/clavulanate 3.1 g every 6 hours
Trial: 9926739
Drug: Imipenem/cilistatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilistatin 500 mg every 6 hours
Trial: 8780327
Drug: Sodium channel
RxNorm normalized name: Sodium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium channel blocking drugs
Trial: 31471833
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse (Tobacco, Alcohol, Psychotropic Drugs)
Trial: 28641363
Drug: OXN PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN PR (up to 160/80 mg daily)
Trial: 18164644
Drug: Pre-treatment stiffness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment stiffness
Trial: 17704850
Drug: Recreational swimming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational swimming combined with asthma education (twice a week for 1 hour over 6 months)
Trial: 17704850
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of inhaled corticosteroids (ICS) and short-acting beta2 agonists (salbutamol as needed)
Trial: 15078472
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (famciclovir or lamivudine + interferon-alpha-2a)
Trial: 11204308
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor (fosinopril) and a statin (pravastatin)
Trial: 11204308
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and lipid‐lowering diet
Trial: 9741405
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose weekly methotrexate (MTX) therapy (7.5‐12.5 mg/week)
Trial: 9768798
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg during sevoflurane anesthesia
Trial: 9768798
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg during isoflurane anesthesia
Trial: 9768798
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg during propofol anesthesia
Trial: 19499738
Drug: Spirulina supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplement (10 grams per day)
Trial: 11246298
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin concentration of 70 g/L, maintained between 70 and 90 g/L)
Trial: 11246298
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin concentration of 100 g/L, maintained between 100 and 120 g/L)
Trial: 31096934
Drug: blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blended cognitive behaviour therapy (bCBT)
Trial: 21881323
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion in CKD patients (Group C)
Trial: 21881323
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion in non-CKD patients (Group D)
Trial: 11173169
Drug: Weekly urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly urine testing (n=16)
Trial: 11173169
Drug: Monthly urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly urine testing (n=18)
Trial: 9430866
Drug: Vancomycin 1000
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg administered during the last hour of CT haemodialysis
Trial: 9430866
Drug: Vancomycin 1000
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg administered after dialysis
Trial: 8238160
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (ampicillin or erythromycin)
Trial: 2862924
Drug: Clorazepate (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate (an anxiolytic)
Trial: 28779478
Drug: Calorie-free, tasteless
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-free, tasteless control solution